This review aims to provide an overview of dysregulation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in epithelial ovarian cancer, with a particular focus on the HGSOC subtype and chemotherapy resistant disease, and the potential targeting of the pathway as a therapeutic option for patients with ovarian cancer. This evidence concerns the gene AKT1 and ovarian carcinoma.